JPM 2022: Vertex’s Trikafta holds the line as company lays groundwork for gene editing launch
Vertex Pharmaceuticals is well known for its slew of cystic fibrosis medications, and newcomer Trikafta is pulling its weight. Over the course of 2021, the med clinch...
Continue Reading →
